Total Payments
$2,265
2024 Payments
$616.03
Companies
19
Transactions
130
Medicare Patients
1,129
Medicare Billing
$112,804
Payment Breakdown by Category
Food & Beverage$2,185 (96.5%)
Education$79.77 (3.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,185 | 127 | 96.5% |
| Education | $79.77 | 3 | 3.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $442.74 | 31 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $263.64 | 17 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $242.54 | 13 | $0 (2024) |
| ITI, Inc. | $195.60 | 13 | $0 (2023) |
| Lundbeck LLC | $188.78 | 11 | $0 (2024) |
| Alkermes, Inc. | $181.99 | 9 | $0 (2023) |
| IDORSIA PHARMACEUTICALS US INC | $139.91 | 3 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $139.16 | 8 | $0 (2024) |
| Indivior Inc. | $130.15 | 6 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $93.18 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $616.03 | 35 | ABBVIE INC. ($137.72) |
| 2023 | $694.55 | 31 | IDORSIA PHARMACEUTICALS US INC ($139.91) |
| 2022 | $584.78 | 40 | ABBVIE INC. ($197.18) |
| 2021 | $369.62 | 24 | ITI, Inc. ($111.60) |
All Payment Transactions
130 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $32.83 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $13.33 | General |
| 11/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: Neuropsychiatry | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $19.75 | General |
| 10/09/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Education | In-kind items and services | $27.27 | General |
| Category: Psychiatry/Psychology | ||||||
| 09/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.03 | General |
| Category: NEUROSCIENCE | ||||||
| 09/13/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: PSYCHIATRY | ||||||
| 08/28/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Neuropsychiatry | ||||||
| 08/07/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 08/07/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 07/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: NEUROSCIENCE | ||||||
| 07/24/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $14.68 | General |
| Category: Neuropsychiatry | ||||||
| 07/16/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: PSYCHIATRY | ||||||
| 07/12/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $18.00 | General |
| Category: PSYCHIATRY | ||||||
| 07/02/2024 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $30.82 | General |
| Category: BH | ||||||
| 06/17/2024 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: BH | ||||||
| 06/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: NEUROSCIENCE | ||||||
| 06/05/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $15.76 | General |
| Category: PSYCHIATRY | ||||||
| 05/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: NEUROSCIENCE | ||||||
| 05/22/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: Neuropsychiatry | ||||||
| 05/10/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), REXULTI | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: PSYCHIATRY | ||||||
| 04/30/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: PSYCHIATRY | ||||||
| 04/25/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: Neuropsychiatry | ||||||
| 04/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: NEUROSCIENCE | ||||||
| 04/12/2024 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 189 | 416 | $51,295 | $16,129 |
| 2022 | 3 | 254 | 604 | $64,012 | $24,382 |
| 2021 | 3 | 306 | 842 | $79,470 | $33,910 |
| 2020 | 3 | 380 | 1,007 | $117,000 | $38,384 |
Total Patients
1,129
Total Services
2,869
Medicare Billing
$112,804
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 48 | 103 | $14,378 | $4,503 | 31.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 34 | 59 | $15,255 | $4,305 | 28.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 49 | $12,656 | $3,604 | 28.5% |
| Q3014 | Telehealth originating site facility fee | Facility | 2023 | 59 | 164 | $3,280 | $1,978 | 60.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 24 | 41 | $5,726 | $1,738 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 78 | 189 | $26,082 | $9,279 | 35.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 40 | 76 | $19,380 | $7,053 | 36.4% |
| Q3014 | Telehealth originating site facility fee | Facility | 2022 | 84 | 269 | $5,380 | $3,558 | 66.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 23 | 30 | $7,650 | $2,594 | 33.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 29 | 40 | $5,520 | $1,897 | 34.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 102 | 297 | $38,537 | $16,477 | 42.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 58 | 104 | $24,927 | $8,768 | 35.2% |
| Q3014 | Telehealth originating site facility fee | Facility | 2021 | 109 | 391 | $7,820 | $5,411 | 69.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 26 | 36 | $4,751 | $2,029 | 42.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 11 | 14 | $3,435 | $1,225 | 35.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 124 | 373 | $85,044 | $24,282 | 28.6% |
| Q3014 | Telehealth originating site facility fee | Facility | 2020 | 126 | 443 | $8,860 | $6,307 | 71.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 70 | 115 | $14,088 | $5,625 | 39.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 28 | 36 | $8,208 | $1,597 | 19.5% |
| Q3014 | Telehealth originating site facility fee | Office | 2020 | 32 | 40 | $800.00 | $573.99 | 71.7% |
About Sharon Lyon-Paul, PMHNP,RN,LISW-S
Sharon Lyon-Paul, PMHNP,RN,LISW-S is a Clinical healthcare provider based in New Lexington, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2012. The National Provider Identifier (NPI) number assigned to this provider is 1689926982.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Sharon Lyon-Paul, PMHNP,RN,LISW-S has received a total of $2,265 in payments from pharmaceutical and medical device companies, with $616.03 received in 2024. These payments were reported across 130 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($2,185).
As a Medicare-enrolled provider, Lyon-Paul has provided services to 1,129 Medicare beneficiaries, totaling 2,869 services with total Medicare billing of $112,804. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical
- Other Specialties Adult
- Location New Lexington, OH
- Active Since 10/10/2012
- Last Updated 01/26/2023
- Taxonomy Code 1041C0700X
- Entity Type Individual
- NPI Number 1689926982
Products in Payments
- VRAYLAR (Drug) $421.66
- INGREZZA (Drug) $242.54
- CAPLYTA (Drug) $211.47
- REXULTI (Drug) $169.40
- QUVIVIQ (Drug) $139.91
- ABILIFY MAINTENA (Drug) $138.08
- PERSERIS (Drug) $130.15
- ARISTADA (Drug) $129.58
- QELBREE (Drug) $80.68
- BRINTELLIX (Drug) $75.52
- COBENFY (Drug) $60.10
- TRINTELLIX (Drug) $54.47
- ABILIFY ASIMTUFII (Drug) $54.02
- Qelbree (Drug) $46.14
- INVEGA SUSTENNA (Drug) $33.57
- Vivitrol (Drug) $28.52
- AUSTEDO (Drug) $27.08
- Auvelity (Drug) $24.45
- VIVITROL (Drug) $23.89
- QULIPTA (Drug) $21.08
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.